Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person
Community-Engaged Pilot Testing of Talking About Cancer (TAC) to Improve Engagement in Advance Care Planning
3 other identifiers
interventional
80
1 country
3
Brief Summary
This clinical trial studies whether telephone-based coaching sessions, Talking About Cancer (TAC), work to improve engagement in advance care planning (ACP) in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and their support person. Participation in ACP, which includes having end of life (EOL) care conversations and completing advance directives (e.g., living will, health care proxy, do not resuscitate order), improves quality EOL care. Despite this, less than half of patients with advanced cancer have EOL care conversations or complete advance directives. TAC coaching sessions are delivered by a social worker over the phone. They are designed to help patients and their support person communicate about ACP, manage the distress these conversations can cause, and participate in the process of ACP with a clear action plan of having goals-of-care conversations and completing advance directives. This may be an effective way to improve ACP participation in advanced cancer patients and their support person.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2026
Shorter than P25 for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 19, 2025
CompletedFirst Posted
Study publicly available on registry
August 26, 2025
CompletedStudy Start
First participant enrolled
April 8, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 12, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 14, 2026
May 29, 2026
February 1, 2026
6 months
August 19, 2025
May 27, 2026
Conditions
Outcome Measures
Primary Outcomes (4)
Enrollment rate (Feasibility)
Feasibility will be examined using enrollment rates. Feasibility cutoffs will be based on prior research and include the following: ≥ 50% of eligible participants will enroll in the study. Low rates of enrollment, including missing data, will indicate low feasibility.
At 6-weeks post-randomization
Intervention session completion rate (Feasibility)
Feasibility will be examined using enrollment and intervention completion rates as outcomes. Feasibility cutoffs will be based on prior research and include the following: ≥ 75% of Talking About Cancer sessions will be delivered with fidelity.
At 6-weeks post-randomization
Acceptability of Intervention Measure (AIM) score (Acceptability)
To analyze intervention acceptability, will examine the median score for the AIM measure, with a median of \>= 4 indicating acceptability (on a 5-point Likert scale where 4=Agree and 5=Completely agree and higher scores indicate higher levels of acceptability).
At 6-weeks post-randomization
Completion rate of study assessments (Feasibility of collecting primary and secondary outcomes)
Feasibility of the study collection procedures will be examined using study-related assessment completion rates and includes the following: ≥ 50% of enrolled patients will adhere to and complete assigned intervention components and study-related assessments.
At baseline, 6-weeks post- randomization, and 12-weeks post-randomization
Secondary Outcomes (11)
Completion of advance directives
At baseline, 6-weeks post-randomization, and 12-weeks post-randomization
Completion of do not resuscitate (DNR) order
At baseline, 6-weeks post-randomization, 12-weeks post-randomization
Completion of living will
At baseline, 6-weeks post-randomization, and 12-weeks randomization
Identification of a health care proxy
At baseline, 6-weeks post-randomization, and 12-weeks post-randomization
Advance care planning (ACP) conversations
At baseline, 6-weeks post-randomization, and 12-weeks post-randomization
- +6 more secondary outcomes
Study Arms (2)
Arm I (TAC sessions)
EXPERIMENTALParticipants attend Talking About Cancer (TAC) telephone-based coaching sessions (2 sessions) designed to support participants in communicating about advance care planning (ACP), managing distress around ACP conversations, engaging in the process of ACP, and completing advance directives over 45-60 minutes each once a week (QW) for 2 weeks.
Arm II (enhanced usual care)
ACTIVE COMPARATORParticipants receive an ACP brochure/handout on study.
Interventions
Attend TAC telephone-based coaching sessions
Receive an ACP brochure/handout
Attend TAC telephone-based coaching sessions
Eligibility Criteria
You may qualify if:
- PATIENT: Current diagnosis of stage III or IV cancer
- PATIENT: Able to provide informed consent
- PATIENT: Fluent in English or Spanish
- PATIENT: Have access to a telephone, computer, or mobile device
- CAREGIVER (SUPPORT PERSON): Person patient indicates provides support
- CAREGIVER (SUPPORT PERSON): English or Spanish speaking
- CAREGIVER (SUPPORT PERSON): 18 years of age or older
- CAREGIVER (SUPPORT PERSON): Able to provide informed consent
You may not qualify if:
- PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer)
- PATIENT: Receiving hospice at the time of enrollment
- PATIENT: Younger than age 18
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Providence Regional Cancer Partnership
Everett, Washington, 98201, United States
Skagit Regional Health Cancer Care Center
Mount Vernon, Washington, 98274, United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Megan Shen, PhD
Fred Hutch/University of Washington Cancer Consortium
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- CARE PROVIDER
- Masking Details
- The study project coordinator will oversee randomization and the research coordinator conducting assessments will remain blind to the condition to which the participant is assigned.
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 19, 2025
First Posted
August 26, 2025
Study Start
April 8, 2026
Primary Completion (Estimated)
October 12, 2026
Study Completion (Estimated)
December 14, 2026
Last Updated
May 29, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share